Physician profile
Don E Eslin
NPI 1659344463
$5,010.93
in general payments reported to CMS, 2019-2025
23 companies · $622 in 2025
The $622 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $221 · 2022: $45.27 · 2023: $306 · 2024: $3,435 · 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,480 · Food and Beverage: $1,271 · Honoraria: $500 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,480.00 |
| Food and Beverage | $1,270.84 |
| Honoraria | $500.00 |
| Education | $112.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $3,090.68 | 2023-2025 | Iwilfin |
| Novartis Pharmaceuticals Corporation | $429.48 | 2019-2024 | |
| Astellas Pharma US INC | $321.19 | 2024-2025 | Cresemba |
| Alexion Pharmaceuticals, INC. | $269.84 | 2023-2025 | Koselugo, Ultomiris |
| Genentech USA, INC. | $137.28 | 2019-2022 | |
| Y-Mabs Therapeutics, INC. | $130.03 | 2025 | Danyelza |
| Amgen INC. | $107.49 | 2019-2024 | Blincyto |
| Jazz Pharmaceuticals INC. | $106.96 | 2020-2025 | |
| Springworks Therapeutics, INC. | $99.89 | 2024-2025 | Gomekli, Ogsiveo |
| Pfizer INC. | $64.74 | 2023-2024 | |
| Global Blood Therapeutics, INC. | $42.03 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.96 | 2020-2025 | |
| Day One Biopharmaceuticals | $29.61 | 2025 | Ojemda |
| Novo Nordisk INC | $22.15 | 2020 | |
| Agios Pharmaceuticals, INC. | $22.03 | 2025 | Pyrukynd |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $21.98 | 2024 | Hemlibra |
| Rare Disease Therapeutics, INC. | $21.95 | 2025 | Xromi |
| Takeda Pharmaceuticals U.S.A., INC. | $20.08 | 2025 | Vpriv |
| Janssen Scientific Affairs, LLC | $19.14 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $12.42 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Eslin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.